Denosumab
BILDYOS, BOMYNTRA, Bilprevda, CONEXXENCE, JUBBONTI, OSPOMYV, Prolia, WYOST, XGEVA
RANK Ligand Inhibitor
NADAC/unit
$1535.8145
No Shortage
Tier 1: 57.8%
PA Req: 159.3%
Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at hi....
vs. brand BILDYOS: Generic saves up to -15258% per unit
Market Intelligence
2025-07-30 Class II Recall: Mckesson Medical-Surgical Inc. Corporate Office
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.